Drug discovery Archives

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […]

October 26, 2022 - 3 minutesmins - By Liza Laws

cancer cell screening drug discovery microplate

News and Trends 26 Oct 2022

Recursion announces $150M private placement

U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

Mike Nally Generate Biomedicines ai drug discovery

Interview 12 Oct 2022

Boosting pharma’s falling productivity with AI in drug discovery

The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael Nally, outlines the firm’s mission to tackle the trend by making drug discovery scalable. Over the decades, the pharma and biopharma industry has suffered a growing stagnation in productivity. According to a report from University College London in 2018, for […]

October 12, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 22 Sep 2022

Emyria starts program with neuroscience drug discovery CRO

Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenic’s drug discovery platform, SmartCube. SmartCube extracts and analyzes behavioral and […]

September 22, 2022 - 2 minutesmins - By Jim Cornall

Startup Scout 22 Sep 2022

Cartography Biosciences unearths cancer immunotherapy targets

Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […]

September 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 21 Sep 2022

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […]

September 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

In a deal with a potential value of $110 million over the next five years, CytoReason has announced an extension of its multi-year partnership with Pfizer. Pfizer will make a $20 million equity investment under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Sep 2022

Recursion adds FAP and C. diff clinical trials

Recursion Pharmaceuticals has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. The phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule […]

September 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Proxidrugs: a new tool to fight pathogens?

Scientists at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany are working with partners to develop a new drug class. Proxidrugs (or proximity-inducing drugs) utilize cells’ waste disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in […]

September 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Jan 2022

Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration

With the close of its Series A round at €48M ($54M), the tissue models company Engitix has shifted its business from providing drug discovery services to developing its own treatment pipeline for liver diseases. When Engitix was spun out of University College London in 2016, the startup primarily aimed to provide tissue models to pharmaceutical […]

January 19, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 17 Jan 2022

Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments

The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […]

January 17, 2022 - 3 minutesmins - By Dan Samorodnitsky

News and Trends 11 Jan 2022

Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia

As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments. According to the deal’s terms, the partners will develop up to 15 small molecule drugs to treat cancer and immunological […]

January 11, 2022 - 4 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Drug discovery

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

Recursion announces $150M private placement

Boosting pharma’s falling productivity with AI in drug discovery

Emyria starts program with neuroscience drug discovery CRO

Cartography Biosciences unearths cancer immunotherapy targets

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

Recursion adds FAP and C. diff clinical trials

Proxidrugs: a new tool to fight pathogens?

Engitix Builds Liver Disease Pipeline with Series A and Drug Collaboration

Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments

Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!